Cited by 548Hormonal and reproductive studiesMenopause: Health Impacts and TreatmentsAdrenal Hormones and Disorders

Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study)

Open access
Jones, T. Hugh, Arver, Stefan, Behre, Hermann M., Buvat, Jacques, Meuleman, Eric, Moncada, Ignacio, Morales, Antonio Martin, Volterrani, Maurizio +4 more·2011·Diabetes Care

Abstract

OBJECTIVE: This study evaluated the effects of testosterone replacement therapy (TRT) on insulin resistance, cardiovascular risk factors, and symptoms in hypogonadal men with type 2 diabetes and/or metabolic syndrome (MetS). RESEARCH DESIGN AND METHODS: The efficacy, safety, and tolerability of a novel transdermal 2% testosterone gel was evaluated over 12 months in 220 hypogonadal men with type 2 diabetes and/or MetS in a multicenter, prospective, randomized, double-blind, placebo-controlled study. The primary outcome was mean change from baseline in homeostasis model assessment of insulin resistance (HOMA-IR). Secondary outcomes were measures of body composition, glycemic control, lipids, and sexual function. Efficacy results focused primarily on months 0-6 (phase 1; no changes in medication allowed). Medication changes were allowed in phase 2 (months 6-12). RESULTS: TRT reduced HOMA-IR in the overall population by 15.2% at 6 months (P = 0.018) and 16.4% at 12 months (P = 0.006). In type 2 diabetic patients, glycemic control was significantly better in the TRT group than the placebo group at month 9 (HbA(1c): treatment difference, -0.446%; P = 0.035). Improvements in total and LDL cholesterol, lipoprotein a (Lpa), body composition, libido, and sexual function occurred in selected patient groups. There were no significant differences between groups in the frequencies of adverse events (AEs) or serious AEs. The majority of AEs (>95%) were mild or moderate. CONCLUSIONS: Over a 6-month period, transdermal TRT was associated with beneficial effects on insulin resistance, total and LDL-cholesterol, Lpa, and sexual health in hypogonadal men with type 2 diabetes and/or MetS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc10-1233

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Substantial evidence implicates testosterone and cortisol in the development of insulin resistance.

    “substantial evidence implicate testosterone and cortisol in the development of insulin resistance.”

    From Sleep, testosterone and cortisol balance, and ageing men (2022) · cites this paper as [89]

    The Conclusions (page not provided) report that testosterone replacement improved insulin resistance in hypogonadal men with type 2 diabetes and/or metabolic syndrome, supporting a role for testosterone. The paper does not address cortisol, and its treatment finding does not establish how insulin resistance develops. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Testosterone treatment improves glycemic control in men with T2DM.

    “improves glycemic control in men with T2DM [89].”

    From Sleep, testosterone and cortisol balance, and ageing men (2022) · cites this paper as [89]

    The Results (Efficacy: Phase 2) report a significant HbA1c difference at nine months in men with type 2 diabetes. But the Conclusions say no reduction was demonstrated at six months and the nine-month finding was confounded by permitted medication changes, so the study could not clearly conclude that treatment improves glycemic control. The claim also omits that the participants were hypogonadal men. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Some studies and meta-analyses highlighted that TRT may reduce body weight in obese men.

    “While some studies and meta-analyses highlighted that TRT may reduce body weight in obese men (34, 35, 36, 37)”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Jones, T. H., Arver, S., Behre, H. M., Buvat, J., Meuleman, E., Moncada, I., Morales, A. M., Volterrani, M., Yellowlees, A., Howell, J. D., Channer, K. S., & TIMES2 Investigators
Affiliations
  • Barnsley Hospital NHS Foundation Trust (GB)
  • Karolinska University Hospital (SE)
  • University Hospital in Halle (DE)
  • Centre d’Etudes et de Traitement de la Pathologie de l’Appareil Reproducteur et de la Psychosomatique (CETPARP), Lille, France
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
  • Hospital Universitario Sanitas La Zarzuela (ES)
  • Department of Urology, Carlos Haya University Hospital, Malaga, Spain
  • Istituti di Ricovero e Cura a Carattere Scientifico (IT)
  • Quantics Consulting Limited, Tweed Horizons, Newtown St Boswells, Scottish Borders, U.K.
  • Kyowa Kirin Farmacéutica, S.L.U. (Spain) (ES)
  • Royal Hallamshire Hospital (GB)
Corresponding author
Jones, T. Hugh
Venue
Diabetes Care
Published
2011-03-21
Volume
34
Issue
4
Pages
828-837
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2102179430
Cited by
548
References
26
Citations by year
2026: 17 · 2025: 16 · 2024: 25 · 2023: 20 · 2022: 31 · 2021: 30 · 2020: 29 · 2019: 32 · 2018: 39 · 2017: 36 · 2016: 41 · 2015: 56 · 2014: 72 · 2013: 48 · 2012: 42
FWCI
45.86
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • Pure Amsterdam UMC (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Funders
Ipsen
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
testosterone replacement therapy, hypogonadism, type 2 diabetes, metabolic syndrome, insulin resistance, transdermal testosterone gel, glycemic control, HbA1c, LDL cholesterol, lipoprotein(a), body composition, sexual function, cardiovascular risk factors
MeSH terms
Adult, Aged, Aged, 80 and over, Body Composition, Diabetes Mellitus, Type 2, Humans, Hypogonadism, Insulin Resistance, Male, Middle Aged, Testosterone, Metabolic Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review